Evidence map›Paper›PMID 32404064›Full record

SynthesisBMC emergency medicine2020

Efficacy and safety of inhaled budesonide on prevention of acute mountain sickness during emergent ascent: a meta-analysis of randomized controlled trials.

Gaurav Nepal, Jayant Kumar Yadav, Jessica Holly Rehrig, Niroj Bhandari, Santosh Baniya, Rakesh Ghimire, Narayan Mahotra

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in BMC emergency medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Gaurav NepalMaharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Kathmandu, Nepal. gauravnepal@iom.edu.np.ORCID 0000-0001-5054-2711
Jayant Kumar YadavMaharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Kathmandu, Nepal.
Jessica Holly RehrigUniversity of New England College of Osteopathic Medicine, Biddeford, ME, USA.
Niroj BhandariKathmandu University School of Medical Sciences, Panauti, Nepal.
Santosh BaniyaMaharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Kathmandu, Nepal.
Rakesh GhimireMaharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Kathmandu, Nepal.
Narayan MahotraMaharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Kathmandu, Nepal.
Tribhuvan University Teaching Hospital · NPKathmandu University · NPNew England College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute Mountain Sickness (AMS) is a pathophysiologic process that occurs in non-acclimated susceptible individuals rapidly ascending to high-altitude. Barometric pressure falls at high altitude and it translates to a decreased partial pressure of alveolar oxygen (PAO2) and arterial oxygen (PaO2). A gradual staged ascent with sufficient acclimatization can prevent AMS but emergent circumstances requiring exposure to rapid atmospheric pressure changes - such as for climbers, disaster or rescue team procedures, and military operations - establishes a need for effective prophylactic medications. This systematic review and meta-analysis aim to analyze the incidence of AMS during emergent ascent of non-acclimatized individuals receiving inhaled budesonide compared to placebo.

methodsThis current meta-analysis was conducted according to the guidance of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We searched PubMed, Google Scholar and Embase for relevant studies. The efficacy of budesonide in reducing incidence of AMS was evaluated by calculating the pooled ORs and 95% CIs. The efficacy of budesonide in maintaining hemoglobin-oxygen saturation was evaluated by calculating standard mean difference (SMD) and 95% confidence intervals.

resultsWe found that at high altitude, inhaled budesonide was effective in reducing the incidence of mild AMS [OR: 0.37; 95% CI, 0.14 to 0.9, p = 0.042] but was ineffective in reducing the incidence of severe AMS [OR: 0.46; 95% CI, 0.14 to 1.41, p = 0.17]. Inhaled budesonide was also effective in maintaining SpO2 (SMD: 0.47; 95% CI, 0.09 to 0.84, p = 0.014) at high altitude. However, it was not effective in maintaining or improving pulmonary function at high altitude. Systematic-review found no adverse effects of budesoide in the dose used for prophylaxis of AMS.

conclusionsOur systematic review showed that prophylactic inhaled budesonide is effective in preventing mild AMS during emergency ascent but not effective in preventing severe AMS. Though statistically significant, authors recommend caution in interpretation of data and questions for further well designed randomized studies to evaluate the role of budesonide in prophylaxis of AMS during an emergent ascent.

Indexed as

Acute DiseaseAdministration, InhalationAltitude SicknessBudesonideGlucocorticoidsHumansRandomized Controlled Trials as TopicBudesonideGlucocorticoidsAcute Mountain sicknessBudesonideDisasterEmergency ascentHigh altitude illnessInhaled budesonideMeta-analysisRescue

Identifiers

PMID32404064
PMCPMC7222565
OpenAlexW3024879928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.